PAVmed Inc. (NASDAQ:PAVM) Short Interest Update

PAVmed Inc. (NASDAQ:PAVM) was the recipient of a large decrease in short interest during the month of May. As of May 29th, there was short interest totaling 8,301 shares, a decrease of 36.3% from the May 14th total of 13,031 shares. Based on an average trading volume of 7,904 shares, the days-to-cover ratio is currently 1.1 days. Approximately 1.0% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

PAVM has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of PAVmed in a research report on Tuesday, April 21st. Ascendiant Capital Markets reduced their price target on PAVmed from $65.00 to $56.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Finally, Wall Street Zen raised PAVmed from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, PAVmed presently has a consensus rating of “Hold” and a consensus target price of $56.00.

PAVmed Price Performance

NASDAQ:PAVM opened at $5.00 on Monday. PAVmed has a 1-year low of $4.50 and a 1-year high of $28.44. The company has a current ratio of 2.02, a quick ratio of 2.02 and a debt-to-equity ratio of 0.70. The firm has a fifty day simple moving average of $7.47 and a 200 day simple moving average of $8.77. The stock has a market capitalization of $5 million, a PE ratio of -0.13 and a beta of 0.58.

PAVmed (NASDAQ:PAVM) last released its earnings results on Friday, May 15th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.48). PAVmed had a negative net margin of 21,914.12% and a negative return on equity of 146.19%. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.07 million. On average, research analysts expect that PAVmed will post -2.74 EPS for the current fiscal year.

Hedge Funds Weigh In On PAVmed

A hedge fund recently raised its stake in PAVmed stock. Geode Capital Management LLC lifted its position in PAVmed Inc. (NASDAQ:PAVM) by 74.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 168,832 shares of the company’s stock after buying an additional 72,258 shares during the quarter. Geode Capital Management LLC owned about 17.23% of PAVmed worth $40,000 as of its most recent SEC filing. Institutional investors own 19.93% of the company’s stock.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.